February 1, 2021 -- The European Medicines Agency (EMA) has recommended the issuance of a conditional marketing authorization (CMA) for AstraZeneca's COVID-19 vaccine in the European Union (EU) for active immunization to prevent COVID-19 in individuals 18 years of age and older.
The authorization follows a positive opinion given by the EMA's Committee for Medicinal Products for Human Use (CHMP) based on data from the rolling review of an analysis from a phase III clinical trial led by the University of Oxford. The analysis included analysis of 23,745 participants ages 18 years and older, accruing 232 symptomatic COVID-19 infections from the U.K. and Brazil phase III trials conducted by the University of Oxford.
The CHMP recommends two doses of the AstraZeneca COVID-19 vaccine, AZD1222, to be administered four-12 weeks apart. The vaccine is based on a replication-deficient chimpanzee adeno-associated viral vector and contains genetic material of the SARS-CoV-2 spike protein. The safety of the vaccine has been confirmed in global clinical trials with over 20,000 participants and confirmed in results published in peer-reviewed journals.
The company anticipates that the EU will approve a CMA shortly and immediately begin immunization across member states.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
